高级检索
当前位置: 首页 > 详情页

Effect of saikosaponins and extracts of vinegar-baked Bupleuri Radix on the activity of β-glucuronidase

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China [2]Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China
出处:
ISSN:

关键词: 4-Nitrophenyl-beta-D-glucuronide beta-glucuronidase saikosaponins vinegar-baked Radix Bupleuri (VBRB)

摘要:
1. In Traditional Chinese Medicine, liver targeting is usually achieved by coadministration with Vinegar-baked Radix Bupleuri (VBRB), but the mechanism is unclear. In this paper, the influence of VBRB on the activity of beta-glucuronidase was investigated and compared with that of saikosaponins. 2. The activity of beta-glucuronidase was measured by microplate reader using a 4-nitrophenyl-beta-D-glucuronide substrate. The change of 4-nitrophenol content was used to characterize the activity of beta-glucuronidase. 3. Bupleurum chinenes were found to be the inhibitor of beta-glucuronidase. The inhibition rate of Bupleurum chinenes extracts BC1 (high molecular weight polysaccharides), BC2 (ethanol soluble/water insoluble component), BC3 (extracted by n-butanol, soluble in water), and BC4 (low molecular weight water soluble parts) on the activity of beta-glucuronidase was found to be 45.15%, 33.94%, 24.94%, and 34.54%, respectively, after 1 h incubation, with BC1 showing the highest inhibition rate. In contrast, the saikosaponins were demonstrated to be the promoter of b-glucuronidase, with promotion rates of 333.56%, 217.04%, 247.87%, 149.75%, and 92.50% for saikosaponin standard samples A, B, B-2, C, and D, respectively, (p<0.05). 4. In conclusion, inhibiting the activity of beta-glucuronidase might be one of the reasons why VBRB could influence drug distribution upon its coadministration with other drugs. Since saikosaponins and VBRB extracts have opposite effect, more attention should be paid to the content of saikosaponins in the extracts upon its application.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 3 区 医学
小类 | 4 区 药学 4 区 毒理学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 药学 4 区 毒理学
JCR分区:
出版当年[2012]版:
Q3 PHARMACOLOGY & PHARMACY Q3 TOXICOLOGY
最新[2023]版:
Q4 PHARMACOLOGY & PHARMACY Q4 TOXICOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2012版] 出版当年五年平均 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者机构: [1]School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
通讯作者:
通讯机构: [1]School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China [2]Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China [*1]School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, 110016, Shenyang, China. [*2]Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Neihuan Xilu, Guangzhou Daxuecheng, 510006, Guangzhou, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号